ABT-418
ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both Alzheimer's disease and ADHD. It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not the α3β4 subtype familiar to nicotine. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.
primaryTopic
ABT-418
ABT-418 is a drug developed by Abbott, that has nootropic, neuroprotective and anxiolytic effects, and has been researched for treatment of both Alzheimer's disease and ADHD. It acts as an agonist at neural nicotinic acetylcholine receptors, subtype-selective binding with high affinity to the α4β2, α7/5-HT3, and α2β2 nicotinic acetylcholine receptors but not the α3β4 subtype familiar to nicotine. ABT-418 was reasonably effective for both applications and fairly well tolerated, but produced some side effects, principally nausea, and it is unclear whether ABT-418 itself will proceed to clinical development or if another similar drug will be used instead.
has abstract
ABT-418 is a drug developed by ...... lar drug will be used instead.
@en
CAS number
147402-53-7
IUPAC name
3-methyl-5-[(2S)-1-methylpyrrolidin-2-yl]-1,2-oxazole
@en
PubChem
thumbnail
Wikipage page ID
17,714,359
Wikipage revision ID
723,543,988
ChEMBL
ChemSpiderID
molecular weight
smiles
CC1=NOC[C@@H]2CCCN2C
StdInChIKey
ILLGYRJAYAAAEW-QMMMGPOBSA-N
Verifiedfields
verifiedrevid
477,235,109
hypernym
comment
ABT-418 is a drug developed by ...... lar drug will be used instead.
@en
label
ABT-418
@en